Bio­con fa­cil­i­ty in Malaysia found to have is­sues once again by the FDA

A re­cent FDA in­spec­tion of a Bio­con man­u­fac­tur­ing fa­cil­i­ty in Malaysia has re­vealed more is­sues re­lat­ing to clean­li­ness.

The reg­u­la­tor in­spect­ed Bio­con’s man­u­fac­tur­ing fa­cil­i­ty in Iskan­dar Put­eri, lo­cat­ed near Sin­ga­pore, be­tween Ju­ly 10 and Ju­ly 20. The site man­u­fac­tures ster­ile drugs, in­clud­ing in­sulin glargine, a biosim­i­lar ver­sion of Sanofi’s Lan­tus.

The 10-page re­port cites clean­ing de­fi­cien­cies for tools and prob­lems re­lat­ed to air­flow in asep­tic ar­eas. It al­so re­port­ed a lack of in­tegri­ty test­ing, which is done to en­sure there are no de­fects, such as tears or pin­holes, be­fore the man­u­fac­tur­ing of ster­ile drug prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER